Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH
Localization of heparin and low-molecular-weight heparin in the rat kidney
Edward Young
1
Department of Pathology and Molecular Medicine, Hamilton, Ontario, Canada
3
Department of Henderson Research, Centre, Hamilton, Ontario, Canada
,
Vivian Douros
3
Department of Henderson Research, Centre, Hamilton, Ontario, Canada
,
Thomas J. Podor
1
Department of Pathology and Molecular Medicine, Hamilton, Ontario, Canada
3
Department of Henderson Research, Centre, Hamilton, Ontario, Canada
,
Stephen G. Shaughnessy
1
Department of Pathology and Molecular Medicine, Hamilton, Ontario, Canada
3
Department of Henderson Research, Centre, Hamilton, Ontario, Canada
,
Jeffrey I. Weitz
2
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
3
Department of Henderson Research, Centre, Hamilton, Ontario, Canada
› Author AffiliationsFinancial support: This work was supported by a grant from the Heart and Stroke Foundation of Ontario (HSFO NA 4191). Dr. Weitz is a Career Investigator of the Heart and Stroke Foundation of Canada and holds the Canada Research Chair in Thrombosis and the HSFO/J.F. Mustard Chair in Cardiovascular Research.
Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are cleared, at least in part, by the kidneys through a poorly understood process. This study was undertaken to explore the mechanism of renal clearance of these drugs. Rats were given fluorescein-5-isothiocyanate (FITC)-labeled UFH or LMWH intravenously. At intervals after injection, rats were euthanized and the kidneys were harvested and subjected to immunohistochemical analysis and fluorescence microscopy. Both UFH and LMWH were localized to renal tubular cells and no immunoperoxidase staining or fluorescence was detected in glomeruli. Autoradiography demonstrated similar intracellular distribution of radio-labeled UFH suggesting that this phenomenon is independent of the method used to label heparin. Fluoresence in the tubules increased as a function of time after UFH injection, but reached a plateau after LMWH injection suggesting that the rate of renal tubular uptake depends on the molecular size of the heparin. When administered prior to FITC-labeled UFH or LMWH, probenecid, a renal organic anion inhibitor, decreased the renal tubular uptake of the heparins, whereas cimetidine, a renal organic cation inhibitor, had no effect. These findings suggest that renal excretion of UFH and LMWH primarily reflects tubular uptake via an organic anion transport mechanism.
2
Boneu B,
Caranobe C,
Cadroy Y.
et al. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin Thromb Hemost 1988; 14: 18-27.
3
Barzu T,
Molho P,
Tobelem G.
et al. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985; 845: 196-203.
6
Fabian I,
Bleiberg I,
Aronson M.
Increased uptake and desulphation of heparin by mouse macrophages in the presence of polycations. Biochim Biophys Acta 1978; 544: 69-76.
7
Caranobe C,
Barret A,
Gabaig AM.
et al. Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY216) in normal and nephrectomized rabbits. Thromb Res 1985; 40: 129-33.
8
Palm M,
Mattsson CH.
Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987; 58: 932-5.
9
Young E,
Cosmi B,
Weitz J.
et al. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost 1993; 70: 625-30.
10
Young E,
Wells P,
Holloway S.
et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71: 300-4.
12
Levine M,
Gent M,
Hirsh J.
et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
13
Koopman MMW,
Prandoni P,
Piovella F.
et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-7.
14
Shum DKY,
Baylis C,
Scott JE.
A micropuncture and renal clearance study in the rat of the urinary excretion of heparin, chondroitin sulphate and metabolic breakdown products of connective tissue proteoglycans. Clin Sci 1984; 67: 205-12.
16
Malsch R,
Guerrini M,
Torri G.
et al. Synthesis of a N’-alkylamine anticoagulant active low-molecular-mass heparin for radioactive and fluorescent labeling. Anal Biochem 1994; 217: 255-64.
20
Beyer KJ,
Russo HF,
Tillson EK.
et al. ‘Benemid’, p-(di-n-propylsulfamyl)-benzoic acid: its renal affinity and its elimination. Am J Physiol 1951; 166: 625-40.
21
de Miranda P,
Good SS,
Yarchoan R.
et al. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDSrelated complex. Clin Pharmacol Ther 1989; 46: 494-500.
22
Lin JH,
Chen IW,
Deluna FA.
et al. Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Dispos 1992; 20: 608-13.
23
Foote EF,
Halstenson CE.
Effects of probenecid and cimetidine on renal disposition of ofloxacin in rats. Antimicrob Agents Chemother 1998; 42: 456-8.
27
Sirak HD,
McCleery RS,
Artz CP.
The effect of carinamide with heparin on the coagulation of human blood: a preliminary report. Surgery 1948; 24: 811.
29
Rubin N,
Lu S,
Horn J.
et al. The safety of low molecular weight heparin (LMWH) in renal failure: A case report of a large retroperitoneal hematoma as a complication of Lovenox use in a patient with renal failure. Blood 1998; 10: 125b (abstract).
30
Nagge J,
Crowther M,
Hirsh J.
Is impaired renal function a contraindication to use of low-molecular-weight heparin?. Arch Intern Med 2002; 162: 2606-09.
This article has been cited by the following publications. The list is generated based on data provided by Crossref.
Dimakakos Evangelos P., Clinical and Applied Thrombosis/Hemostasis. 2018; 697. DOI: 10.1177/1076029617729215 van der Heijden Charlotte D. C. C., British Journal of Clinical Pharmacology. 2022; 2982. DOI: 10.1111/bcp.15208 Myint Khin-Mar, Diabetes. 2006; 2510. DOI: 10.2337/db06-0221 Johansen Kristian B, Experimental Hematology & Oncology. 2013; DOI: 10.1186/2162-3619-2-21 Hiebert Linda M., Journal of Cardiovascular Pharmacology and Therapeutics. 2017; 264. DOI: 10.1177/1074248416667601 Xu Yongmei, Science Translational Medicine. 2017; DOI: 10.1126/scitranslmed.aan5954